Interventional Oncology for Hepatic Malignancies

Interventional Oncology for Hepatic Malignancies

Lecture Summary — Prof. Kevin Kim, MD | University of Maryland School of Medicine

1. Main Clinical Topics Discussed

• Interventional oncology (IO) approaches to primary and metastatic hepatic malignancies
• Hepatocellular carcinoma (HCC) as the primary focus, with reference to cholangiocarcinoma, neuroendocrine/carcinoid metastases, and benign hepatic lesions
• Ablative and transcatheter locoregional therapies
• Integration of interventional oncology with immunotherapy (immuno-oncology)
• Emerging technologies: robotic guidance, virtual/augmented reality, and advanced imaging suites

2. Key Learning Points, Guidelines, and Recommendations

BCLC Staging and Treatment Selection

• The Barcelona Clinic Liver Cancer (BCLC) staging system remains the primary framework in the U.S. and Europe, particularly at transplant centers
• Patients in early and intermediate BCLC stages represent the population most likely to benefit from curative or locoregional intent therapy
• Clinical reality often diverges from strict BCLC criteria — experienced clinicians develop nuanced patient-level judgment integrating imaging, laboratory data (e.g., AFP), and clinical context

HCC Survival Hierarchy (General)

• Transplantation and surgical resection → highest survival
• Ablative therapies → second tier
• Transcatheter therapies (e.g., TACE, Y-90 radioembolization) → intermediate tier
• Systemic therapy and radiation → lower tier
• This survival hierarchy has remained broadly stable over decades, though novel therapies are beginning to shift outcomes

Spectrum of Locoregional Ablative Therapies

• Radiofrequency ablation (RFA): widely used, particularly in Asia and Europe
• Microwave ablation (MWA): current workhorse in the U.S.
• Cryoablation: increasing adoption in Asia; role in metastatic disease
• Laser ablation: established role in Europe
• Irreversible electroporation (IRE)/Nano-Knife and pulsed electric field ablation: newer modalities with emerging indications
• High-Intensity Focused Ultrasound (HIFU): non-thermal ultrasound-guided option under investigation

Transcatheter Therapies

• Bland embolization, conventional TACE (transarterial chemoembolization), and Y-90 radioembolization represent the core transcatheter armamentarium
• Y-90 radioembolization demonstrated utility even in advanced-stage (BCLC-C) patients with portal vein thrombosis (PVT), enabling downstaging to transplantation

Key Practical Clinical Observations

• Single, well-capsulated tumors (3–4 cm) respond well to virtually any modality
• Large tumors (>20 cm) and select cases with limited portal vein invasion can achieve favorable outcomes with appropriate IO therapy
• Diffuse infiltrative HCC and bilateral main portal vein tumor thrombus (PVT4) carry poor prognosis regardless of treatment approach
• Elderly patients (example cited: 94-year-old with NASH-related HCC) can safely undergo locoregional therapy with excellent outcomes (complete response, tumor-free survival)

3. Specific Clinical Data, Statistics, and Study Results Cited

• A patient with BCLC-C stage HCC and portal vein invasion treated with Y-90 radioembolization achieved sufficient downstaging to undergo liver transplantation approximately two years post-treatment — predating the current era of systemic immunotherapy combination regimens
• Ablation procedures in high-risk patients (DLCO >27%, severe comorbidities) completed within approximately 30 minutes via percutaneous approach with minimal procedural morbidity
• A 94-year-old patient with NASH and solitary HCC achieved complete radiologic response and remained tumor-free for years following locoregional ablation
• AFP of 9,000 ng/mL cited as elevated but not necessarily precluding locoregional treatment in multifocal disease

*(Note: The transcript is largely narrative/experiential; formal trial data or landmark study citations were not fully captured in the available excerpt.)*

4. Practical Takeaways for